DARAXONRASIB E K PANCREAS. IL TRIAL RASolute 302 NEL COMMENTO DI VINAY PRASAD. UTILE COMMENTO !

CHIRURGIA, GASTROENTEROLOGIA, NEWSLETTER, ONCOLOGIA, PANCREAS E VIE BILIARI

Forwarded this email? Subscribe here for more Daraxonrasib in pancreas cancer. Vinay Prasad May 31 READ IN APP RASolute 302 trial has rightly generated significant excitement at ASCO2026 and I share this excitement. Pancreatic cancer has for long been a challenge for oncologists and KRAS is the classic ‘undruggable’ target. Any advance here is notable and must…

DARAXONRASIB E K PANCREAS: NEL TRIAL RASolute 302 MOSTRA EFFICACIA NEI PAZIENTI GIA’ TRATTATI. LA PLATEA ASCO IN PIEDI PER UNA STANDING OVATION. IN CONTEMPORANEA CON “NEJM” (FREE)

CHIRURGIA, GASTROENTEROLOGIA, NEWSLETTER, ONCOLOGIA, PANCREAS E VIE BILIARI, Senza categoria

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer Brian M. Wolpin et al. for the RMC-6236-001 Investigators Abstract Background Current therapies for patients with pancreatic ductal adenocarcinoma (PDAC) provide modest benefit. Activating RAS mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate–bound mutant and wild-type RAS.…